Search - tctmd.com

Displaying 101 - 120 of 165

Sort: Relevancy | Date

News Conference News ESC 2018

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Todd Neale

August 27, 2018

News Daily News

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Michael O'Riordan

August 02, 2018

News Daily News

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

Yael L. Maxwell

June 25, 2018

News Conference News EAS 2018

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

Yael L. Maxwell

May 14, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Daily News

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Michael O'Riordan

February 02, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Merck Calls Quits on CETP Inhibitor Anacetrapib

Michael O'Riordan

October 12, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Michael O'Riordan

August 29, 2017

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

Advertisement

Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm

Starting Low and Going Lower: Some Benefit to Very Low LDL Levels

Clinical Benefit of Lowering Lp(a) Is Proportional to Its Absolute Reduction: Mendelian Randomization Analysis

ORION 1 Data Show Lipoprotein-Lowering Beyond LDL Cholesterol With Injectable Inclisiran

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

No Cardiovascular Benefit With Omega-3 Fatty Acid Supplements: Meta-analysis

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Merck Calls Quits on CETP Inhibitor Anacetrapib

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

Anacetrapib Finds (Modest) Success Where All Other CETP Inhibitors Failed

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content